NYSE:LLYPharmaceuticals
Should Lilly’s Nimbus Obesity Drug Alliance Reshape How Eli Lilly (LLY) Investors View Its Pipeline Strategy?
Nimbus Therapeutics recently announced a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly to develop a novel oral obesity and metabolic disease treatment, with Nimbus eligible for US$55.00 million upfront and near-term milestones and up to about US$1.30 billion in longer-term payments plus tiered royalties.
The deal deepens Lilly’s bench in oral obesity therapies just as competition intensifies, allowing it to pair Nimbus’ computational chemistry...